In Mar 2022, AMDL received certificate of CAP EQAP 2021 March, 2022 Home > Resources > Press Release > In Mar 2022, AMDL received certificate of CAP EQAP 2021 Good news! AMDL Molecular Laboratory passed CAP-PT(NGSST) with full marks.
AMDL launched the Cancer Diagnostic Test Feb, 2022 Home > Resources > Press Release > AMDL launched the Cancer Diagnostic Test We are delighted and proud to announce that, after a long preparation of our laboratory, we have launched our First AMDL Lung and Colorectal Cancer Genetic Test!If you are interested, please feel free to contact and email us for the details of our service. Get One Step Ahead of Cancer Contact us
Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Aug, 2021 Home > Resources > Press Release > Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Pillar Biosciences announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its ONCO/Reveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors. Please click here for details.
Renovation of molecular diagnostic laboratory in HKSTP finished Jul, 2020 Home > Resources > Press Release > Renovation of molecular diagnostic laboratory in HKSTP finished Joined Hong Kong Science and Technology (HKSTP) as a Tenant company and started to build a molecular diagnostic laboratory in HKSTP. AMDL started its centralized laboratory in the HKSTP, where it is a hub of talents and innovations in R&D industry in Hong Kong. We hope to encounter more opportunities with the world-class developers here.
China Biotech Services Holdings Limited and Pillar Biosciences entered into a strategic partnership Jan, 2019 Home > Resources > Press Release > China Biotech Services Holdings Limited and Pillar Biosciences entered into a strategic partnership Under the terms of strategic agreement, China Biotech Services Holdings Limited and Pillar formed a joint venture, Asia Molecular Diagnostic Laboratory Limited (AMDL). We pledge to do our best to become one of the top-notch oncogene diagnostics centres in Hong Kong and Asia. We look forward to your continued support to our company.
